News Story

OX2 Reaches Recommended Phase 2 Dose Milestone in Pediatric Brain Tumor Trial

May 1, 2026 | News Story, Featured

Trial advances forward with no dose-limited toxicities observed to date. MINNEAPOLIS (May 1, 2026) – OX2 Therapeutics, Inc. today announces it has reached its Recommended Phase 2 Dose (RP2D) in its ongoing clinical trial evaluating ARL200 + GBM6-AD Vaccine in...

Vaccine Trial Launched to Fight Pediatric Brain Cancer

Feb 12, 2025 | News Story

University of Minnesota researchers have launched a promising vaccine trial targeting childhood brain cancer, offering hope to improve survival and quality of life for young patients.